Beijing Airdoc Technology Co (HKSE:02251) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02251 Beijing Airdoc Technology Co Ltd HKSE:02251
64 GF Score
Price HK$7.90
GF Value HK$15.18
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Beijing Airdoc Technology Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02251
64GF Score
Beijing Airdoc Technology Co Ltd HKSE:02251
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beijing Airdoc Technology Co (HKSE:02251) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Airdoc Technology Co stock appears to be undervalued. The current stock price of HK$7.90 is trading 48% below its estimated GF Value™ of HK$15.18. GuruFocus considers Beijing Airdoc Technology Co to be Significantly Undervalued.

Key valuation signals for HKSE:02251:

  • FFO:
  • GF Value™: HK$15.18 vs. price of HK$7.90 (48% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02251 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Airdoc Technology Co Business Description

Address West Third Ring North Road, Room 21, 4th Floor, Building 2, A2 Yard, Haidian District, Beijing, CHN, 100089
Beijing Airdoc Technology Co Ltd provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions in China. Leveraging retinal imaging, multimodal data analyses, and AI deep learning algorithms, the company's solution differs from traditional chronic disease early detection and diagnosis, enabling non-invasive, accurate, fast, effective, and scalable detection and diagnosis of chronic diseases in both medical institutions and consumer healthcare providers. The Company derives revenue from the provision of AI-based software solutions, sales of hardware devices, and other services. Geographically, the company generates the majority of its revenue from Mainland China.
64GF Score

Get the complete analysis for HKSE:02251

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.90
Price
HK$15.18
GF Value